Total Dystrophic Onychomycosis Successfully Treated with Efinaconazole Topical Solution in Times of Coronavirus Disease of 2019: A Case Study.
J Am Podiatr Med Assoc
; 112(2)2022 Apr 27.
Article
in English
| MEDLINE | ID: covidwho-1988432
ABSTRACT
Toenail onychomycosis is a common condition that is equally challenging for podiatrists and patients. This case study documents a 26-year-old woman with bilateral total dystrophic onychomycosis of at least 5 years' duration. She had previously failed to respond to treatment with ciclopirox nail lacquer 8% and, despite hiding her condition with nail polish, was suffering from embarrassment, distress, and low self-esteem. At initial consultation, 100% of both great toenails was affected. After discussion of all treatment options, the patient opted for topical efinaconazole 10% solution, once daily for 48 weeks. Significant improvement was noted at the first (4-week) assessment period. This improvement was maintained through each subsequent virtual consultation, and complete cure was seen at a 30-week follow-up visit. To the author's knowledge, this is the first published report on the use of efinaconazole in total dystrophic onychomycosis. It suggests that the product may be effective in patients with even the most severe and treatment-recalcitrant disease, who are unwilling or unable to tolerate systemic antifungal therapy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Onychomycosis
/
Coronavirus
/
Foot Dermatoses
Type of study:
Case report
/
Cohort study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
Language:
English
Journal subject:
Podiatry
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS